September 8, 2022Open Access
Parenteral Antiplatelet Drugs in ST-Elevation Myocardial Infarction: Current Status and Future Directions
Structured PICO
P
Population
STEMI patients
I
Intervention
Parenteral antiplatelet drugs (cangrelor, selatogrel, zalunfiban)
Novel parenteral antiplatelet drugs such as cangrelor, selatogrel, and zalunfiban are being developed to provide rapid, potent, and safe platelet inhibition for prehospital administration in STEMI.
Abstract
inhibitors, but their use has been limited by the increased risk of major bleeding and thrombocytopenia. Hence, there is a clinical need to refine drugs that deliver rapid, effective, yet safe platelet inhibition in the setting of STEMI. Novel parenteral antiplatelet drugs, such as cangrelor, selatogrel, and zalunfiban, have been recently developed to achieve rapid, potent antiplatelet effects while preserving hemostasis. We provide a description of currently available parenteral antiplatelet agents and of those in clinical development for prehospital administration in STEMI patients.